uCity Square's 3675 Market Nears Full Occupancy

by Steve Lubetkin, Globest.com
Global biotechnology company Amicus Therapeutics will occupy space in uCity Square’s newest building, 3675 Market Street, for its newly-announced Global Research and Gene Therapy Center of Excellence.
With the Amicus announcement, 3675 Market is now 90% leased just 90 days after opening in November. Amicus’s commitment in the building totals 75,000 square feet of office and lab space over three floors and is expected to be open in the second half of 2019.

The space will eventually hold up to 200 employees. A group of Amicus researchers is already occupying space in the building as a client of BioLabs@CIC Philadelphia, a state-of-the art co-working wet lab and office facility.
“Like all of our facilities, the BioLabs@CIC Philadelphia site is designed to stimulate exciting science and creative collaboration,” says Dr. Laura Holberger, vice president of strategic partnerships, BioLabs. “Amicus brings valuable real-life experience and world-class science to our Philadelphia community and our national network.”

Developed by Wexford Science & Technology in partnership with the University City Science Center and real estate investment trust Ventas, 3675 Market Street is a 14-story, 345,000-square-foot building that combines several unique but complementary innovation assets including CIC Philadelphia, BioLabs@CIC Philadelphia, Science Center commercialization programs, Quorum, Venture Café Philadelphia, and FirstHand.

“We’re thrilled to welcome Amicus Therapeutics to 3675 Market,” says Science Center president and CEO Steve Zarrilli. “The establishment of the Global Research and Gene Therapy Center of Excellence is a testament to the vitality of the vibrant community here at uCity Square and Philadelphia as a leader in biotechnology and gene therapy research.”
3675 Market is the latest addition to uCity Square, a 6.5 million square-foot mixed-use knowledge community consisting of office, laboratory, clinical, residential, and retail space to enable university and corporate research, entrepreneurial activity, and community engagement.

“Attracting biotechnology industry leaders like Amicus to uCity Square validates the power of the knowledge community business model in developing a platform that encourages innovation through collaboration with leading research universities,” says Joe Reagan, senior vice president at Wexford Science & Technology. “The decision to come to 3675 is a testament to the diverse combination of partners and offerings within our ecosystem that provide flexibility and scalability for organizations like Amicus.”

Amicus Therapeutics chairman and CEO John F. Crowley acknowledged the proximity to collaborators at the University of Pennsylvania and other major academic centers and hospitals in the area as a tremendous opportunity to advance their commitment to gene therapies and novel high-quality medicines for people living with rare metabolic diseases as part of their announcement.
www.omegare.com